Characterization of Human γδ T Lymphocytes Infiltrating Primary Malignant Melanomas

被引:107
作者
Cordova, Adriana [2 ]
Toia, Francesca [2 ]
La Mendola, Carmela [1 ]
Orlando, Valentina [1 ]
Meraviglia, Serena [1 ]
Rinaldi, Gaetana [2 ]
Todaro, Matilde [2 ]
Cicero, Giuseppe [2 ]
Zichichi, Leonardo [3 ]
Donni, Paolo Li
Caccamo, Nadia [1 ]
Stassi, Giorgio [2 ]
Dieli, Francesco [1 ]
Moschella, Francesco [2 ]
机构
[1] Univ Palermo, Dipartimento Biopatol & Biotecnol Med & Forensi, Palermo, Italy
[2] Univ Palermo, Dipartimento Discipline Chirurg & Oncol, Palermo, Italy
[3] Azienda Osped S Antonio Abate, Unita Operativa Dermatol, Trapani, Italy
关键词
OVERCOMING IMMUNOLOGICAL-TOLERANCE; PHASE-I; METASTATIC MELANOMA; MEVALONATE PATHWAY; TARGETING CTLA-4; CELL-THERAPY; TUMOR-CELLS; LYMPH-NODES; IMMUNOTHERAPY; CANCER;
D O I
10.1371/journal.pone.0049878
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
T lymphocytes are often induced naturally in melanoma patients and infiltrate tumors. Given that gamma delta T cells mediate antigen-specific killing of tumor cells, we studied the representation and the in vitro cytokine production and cytotoxic activity of tumor infiltrating gamma delta T cells from 74 patients with primary melanoma. We found that gamma delta T cells represent the major lymphocyte population infiltrating melanoma, and both V delta 1(+) and V delta 2(+) cells are involved. The majority of melanoma-infiltrating gamma delta cells showed effector memory and terminally-differentiated phenotypes and, accordingly, polyclonal gamma delta T cell lines obtained from tumor-infiltrating immune cells produced IFN-gamma and TNF-alpha and were capable of killing melanoma cell lines in vitro. The cytotoxic capability of V delta 2 cell lines was further improved by pre-treatment of tumor target cells with zoledronate. Moreover, higher rate of gamma delta T cells isolation and percentages of V delta 2 cells correlate with early stage of development of melanoma and absence of metastasis. Altogether, our results suggest that a natural immune response mediated by gamma delta T lymphocytes may contribute to the immunosurveillance of melanoma.
引用
收藏
页数:9
相关论文
共 55 条
[1]  
[Anonymous], J IMMUNOL
[2]  
[Anonymous], INTUITIVE BIOSTATIST
[3]  
[Anonymous], CANC RES
[4]  
Atkins MB, 2000, CANCER J SCI AM, V6, pS11
[5]   Final Version of 2009 AJCC Melanoma Staging and Classification [J].
Balch, Charles M. ;
Gershenwald, Jeffrey E. ;
Soong, Seng-jaw ;
Thompson, John F. ;
Atkins, Michael B. ;
Byrd, David R. ;
Buzaid, Antonio C. ;
Cochran, Alistair J. ;
Coit, Daniel G. ;
Ding, Shouluan ;
Eggermont, Alexander M. ;
Flaherty, Keith T. ;
Gimotty, Phyllis A. ;
Kirkwood, John M. ;
McMasters, Kelly M. ;
Mihm, Martin C., Jr. ;
Morton, Donald L. ;
Ross, Merrick I. ;
Sober, Arthur J. ;
Sondak, Vernon K. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6199-6206
[6]   IL-21 enhances the potential of human γδ T cells to provide B-cell help [J].
Bansal, Raj R. ;
Mackay, Charles R. ;
Moser, Bernhard ;
Eberl, Matthias .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2012, 42 (01) :110-119
[7]   Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group [J].
Bedikian, Agop Y. ;
Millward, Michael ;
Pehamberger, Hubert ;
Conry, Robert ;
Gore, Martin ;
Trefzer, Uwe ;
Pavlick, Anna C. ;
DeConti, Ronald ;
Hersh, Evan M. ;
Hersey, Peter ;
Kirkwood, John M. ;
Haluska, Frank G. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4738-4745
[8]   Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma [J].
Bennouna, Jaafar ;
Bompas, Emmanuelle ;
Neidhardt, Eve Marie ;
Rolland, Frederic ;
Philip, Irene ;
Galea, Celine ;
Salot, Samuel ;
Saiagh, Soraya ;
Audrain, Marie ;
Rimbert, Marie ;
Micheaux, Sylvie Lafaye-de ;
Tiollier, Jerome ;
Negrier, Sylvie .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (11) :1599-1609
[9]   Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies [J].
Berger, Raanan ;
Rotem-Yehudar, Rinat ;
Slama, Gideon ;
Landes, Shimon ;
Kneller, Abraham ;
Leiba, Merav ;
Koren-Michowitz, Maya ;
Shimoni, Avichai ;
Nagler, Arnon .
CLINICAL CANCER RESEARCH, 2008, 14 (10) :3044-3051
[10]   Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy [J].
Blank, C ;
Gajewski, TF ;
Mackensen, A .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (04) :307-314